First patients sought for groundbreaking engineered immune cell cancer trial
NCT ID NCT07488923
Summary
This is the first study in people to test the safety and early effects of an experimental cell therapy called ML261. It is for adults with advanced small cell lung cancer or certain related neuroendocrine cancers that have come back or stopped responding to standard treatments. Doctors will collect a patient's own immune cells, genetically modify them to better target cancer, and infuse them back to see if they can fight the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER (SCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.